US4234571A
(en)
*
|
1979-06-11 |
1980-11-18 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
|
DE3411224A1
(de)
*
|
1984-03-27 |
1985-10-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
US4705778A
(en)
*
|
1985-10-22 |
1987-11-10 |
Sri International |
Orally active LHRH analogs
|
JPH0284272U
(fr)
*
|
1988-12-20 |
1990-06-29 |
|
|
JP2672677B2
(ja)
*
|
1989-02-09 |
1997-11-05 |
タツプ・フアーマシユーテイカルズ・インコーポレイテツド |
Lhrh同族体
|
DE69022722T2
(de)
*
|
1989-03-10 |
1996-05-02 |
Endorecherche Inc |
Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
KR920703065A
(ko)
*
|
1989-07-07 |
1992-12-17 |
원본미기재 |
안드로겐 관련질병의 치료방법
|
JP2959839B2
(ja)
*
|
1989-07-07 |
1999-10-06 |
アンドルシェルシュ・インコーポレイテッド |
性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
|
GB9112859D0
(en)
*
|
1991-06-14 |
1991-07-31 |
Ici Plc |
Peptide process
|
RU2141967C1
(ru)
*
|
1992-05-21 |
1999-11-27 |
Андорешерш Инк. |
ИНГИБИТОРЫ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
CA2192782C
(fr)
|
1995-12-15 |
2008-10-14 |
Nobuyuki Takechi |
Production de microsphere
|
CA2192773C
(fr)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Obtention d'une preparation a liberation prolongee pour injection
|
US6448031B1
(en)
|
1996-06-13 |
2002-09-10 |
Itoham Foods Inc. |
Process for producing LH-RH derivatives
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
US6242421B1
(en)
|
1997-11-06 |
2001-06-05 |
Richard Lloyd Bowen |
Methods for preventing and treating Alzheimer's disease
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
ES2154590B1
(es)
|
1999-05-20 |
2001-11-01 |
Lipotec Sa |
Procedimiento de sintesis de peptidos en fase solida
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
DE10032256C2
(de)
*
|
2000-07-03 |
2003-06-05 |
Infineon Technologies Ag |
Chip-ID-Register-Anordnung
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
PT2269603E
(pt)
|
2001-02-19 |
2015-09-09 |
Novartis Ag |
Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
|
JP4477303B2
(ja)
|
2001-05-16 |
2010-06-09 |
ノバルティス アーゲー |
N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
CA2466659A1
(fr)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Agents anticancer
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
US20030144203A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
CN1652757B
(zh)
|
2002-05-16 |
2012-02-08 |
诺瓦提斯公司 |
Edg受体结合剂在癌症中的应用
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
AU2003299659A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Durect Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
EP1651612B9
(fr)
|
2003-07-22 |
2012-09-05 |
Astex Therapeutics Limited |
Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3)
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
CN1964970B
(zh)
|
2004-04-07 |
2011-08-03 |
诺瓦提斯公司 |
Iap的抑制剂
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
CN101863971A
(zh)
*
|
2004-06-25 |
2010-10-20 |
武田药品工业株式会社 |
转移素衍生物及其用途
|
JP5285275B2
(ja)
*
|
2004-09-17 |
2013-09-11 |
デュレクト コーポレーション |
制御されたデリバリーシステム
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
WO2006077428A1
(fr)
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Composes pharmaceutiques
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
ES2336826T3
(es)
|
2005-05-03 |
2010-04-16 |
Novetide, Ltd. |
Procedimientos para la produccion de un peptido que presenta una amida c-terminal.
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
AR058065A1
(es)
|
2005-09-27 |
2008-01-23 |
Novartis Ag |
Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20090317489A1
(en)
|
2006-05-09 |
2009-12-24 |
Hanspeter Nick |
Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
|
AU2007302263A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as P13K lipid kinase inhibitors
|
WO2008044041A1
(fr)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
EP2073807A1
(fr)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
AU2007325918B2
(en)
|
2006-11-03 |
2013-10-17 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
EP2491923A3
(fr)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinaisons d'agents thérapeutiques pour traiter le cancer
|
JP2011506318A
(ja)
*
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
経口医薬製剤
|
EP2268612B1
(fr)
|
2008-03-24 |
2014-08-20 |
Novartis AG |
Inhibiteurs de métalloprotéases matricielles à base d'arylsulfonamides
|
CN102036955B
(zh)
|
2008-03-26 |
2013-03-27 |
诺瓦提斯公司 |
脱乙酰酶b的异羟肟酸盐为基础的抑制剂
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
CA2744937C
(fr)
*
|
2008-11-28 |
2017-02-28 |
Novartis Ag |
Combinaison pharmaceutique comprenant un inhibiteur hsp 90 et un inhibiteur mtor
|
WO2010083617A1
(fr)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
|
WO2010088335A1
(fr)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Benzimidazoles substitués destinés au traitement d'astrocytomes
|
DK2445903T3
(da)
|
2009-06-26 |
2014-06-23 |
Novartis Ag |
1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
WO2011020861A1
(fr)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Composés d'oximes hétérocycliques
|
BR112012008075A2
(pt)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
|
CA2773661A1
(fr)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Derives ethers d'heteroaryles bicycliques
|
EP2496575B1
(fr)
|
2009-11-04 |
2014-04-30 |
Novartis AG |
Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
WO2011070030A1
(fr)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Dérivés sulfonamides hétérocycliques
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
KR20150039882A
(ko)
|
2010-06-16 |
2015-04-13 |
앙도르쉐르슈 인코포레이티드 |
에스트로겐-관련 질병의 치료 또는 예방 방법
|
EP2582681A1
(fr)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Dérivés de 1,3 dihydro-benzoimidazol-2-ylidène-amine à substitution pipéridinyle
|
WO2011157787A1
(fr)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Dérivés de 1,3‑dihydro-benzoimidazol-2-ylidène-amine à substitution biphényle
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
WO2012035078A1
(fr)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
Inhibiteurs de la 17α-hydroxylase/c17,20-lyase
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
CN103649073B
(zh)
|
2011-04-28 |
2016-04-13 |
诺瓦提斯公司 |
17α-羟化酶/C17,20-裂合酶抑制剂
|
JP2014513727A
(ja)
|
2011-05-16 |
2014-06-05 |
ジェンザイム・コーポレーション |
Cxcr4拮抗薬の使用
|
MX2013014398A
(es)
|
2011-06-09 |
2014-03-21 |
Novartis Ag |
Derivados de sulfonamida heterociclicos.
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
CN103608349A
(zh)
|
2011-06-27 |
2014-02-26 |
诺瓦提斯公司 |
四氢-吡啶并-嘧啶衍生物的固体形式和盐
|
CA2848809A1
(fr)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
EP2794594A1
(fr)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Dérivés quinoline
|
JO3398B1
(ar)
|
2011-12-22 |
2019-10-20 |
Novartis Ag |
مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
|
US9126979B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
WO2013096060A1
(fr)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
WO2013096051A1
(fr)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Composés pour inhiber l'interaction de bcl-2 avec des partenaires de liaison
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
UY34807A
(es)
|
2012-05-16 |
2013-12-31 |
Novartis Ag |
Derivados monocíclicos de heteroarilcicloalquil- diamina
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
EP2861256B1
(fr)
|
2012-06-15 |
2019-10-23 |
The Brigham and Women's Hospital, Inc. |
Compositions pour le traitement du cancer et leurs procédés de préparation
|
WO2014027300A1
(fr)
|
2012-08-13 |
2014-02-20 |
Novartis Ag |
Dérivés hétéroaryle cycloalkyldiamine bicycliques en tant qu'inhibiteurs de tyrosine kinases de la rate (syk)
|
MD20150043A2
(ro)
|
2012-10-02 |
2015-08-31 |
Epitherapeutics Aps |
Inhibitori ai histon-demetilazelor
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(fr)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Composés de purinone substitués
|
WO2014128612A1
(fr)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Dérivés de quinazolin-4-one
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
CA2905131A1
(fr)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions ayant un agent de modification rheologique pour reduire une variabilite de dissolution
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015022664A1
(fr)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Composés et compositions utiles comme inhibiteurs de mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(fr)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Composés et compositions utiles comme inhibiteurs de mek
|
CA2920059A1
(fr)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Composes d'aminopyrimidine substituee et procedes d'utilisation
|
KR20160101027A
(ko)
|
2014-01-15 |
2016-08-24 |
노파르티스 아게 |
제약 조합물
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3126345A1
(fr)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibiteurs d'histones déméthylases
|
WO2015153345A1
(fr)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Agents thérapeutiques combinatoires supramoléculaires
|
SG11201701182VA
(en)
|
2014-08-27 |
2017-03-30 |
Gilead Sciences Inc |
Compounds and methods for inhibiting histone demethylases
|
WO2017044434A1
(fr)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Composés hétéroaryle substitués et leurs méthodes d'utilisation
|
EP3710006A4
(fr)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
Composés hétéroaryle substitués et leurs méthodes d'utilisation
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
JP2022550357A
(ja)
*
|
2019-09-26 |
2022-12-01 |
エス.アイ.エス. シュロフ イノベイティブ サイエンス リミテッド |
抗老化組成物およびその使用方法
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
KR20220140711A
(ko)
|
2020-01-13 |
2022-10-18 |
듀렉트 코퍼레이션 |
불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
|